Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by wildbird1on Apr 05, 2020 10:47am
148 Views
Post# 30880484

RE:RE:RE:Lindt

RE:RE:RE:Lindt In the Jan 27, 2020 PressRelease SZLS said " LIND is expected to be fully converted within the next 2-3 months".
That would be end of April 2020.

Because of the Covid-19 crisis, 40 million shares were traded in just 4 days.
We could assume that when the 2-3 months timeline was enunciated, SZLS didn't expect 40 million shares being traded in just 4 days.

Because of the very large number of shares traded lately (it will continue) LIND could be fully converted as we speak, or very very close to be.

When that does happen it will be very good news for the longs on this board.


wildbird1 wrote:
Unfortunately your numbers are a little on the short side.

In the text that you provided it does said" The agreement was first announced on June 1, 2018".

In the june 1, 2018 agreement the total number of shares  given to LIND is closer to 60 million. 
The positive side of all of this Lind story, is that in the last 4 days approximately 40 million shares were traded (all Exchange).
A big number of these shares must have been traded by LIND.

okletsmakemoney wrote:

I'm not sure if my math is right... $750000/.04 =18,750,000 shares + 2,552,756 warrants. please correct me if I'm wrong, as I also want to know the answer. Thx

TORONTO, ON / ACCESSWIRE / April 22, 2019 / 
GeneNews Limited (TSX: GEN) ("GeneNews" or the "Company") announced today that Lind Asset Management XI, LLC ("Lind") has increased its funding under the First Convertible Security of the Convertible Security Funding Agreement (the "Agreement") dated May 31, 2018 between the Company and Lind by CDN$750,000 (the "Additional Funding"). The Agreement was first announced on June 1, 2018.

"This is the second time Lind has agreed to provide additional funding for us," said James R. Howard-Tripp, Chairman and CEO of GeneNews. "It is not only good to have their strong support of our objectives but it is also an effective way for us to finance. For reference, our share price was approximately $0.04 at the time of our January financing with Lind, and the last two Conversions were priced at $0.1289 and $0.1357."

Under the terms of the Agreement, Lind has advanced an additional CDN$750,000, less a closing fee of CDN$37,500, in consideration for the increase in the First Convertible Security in the amount of CDN$900,000. The term of the Agreement remains at the original 30 months. GeneNews and Lind have also agreed to increase the potential monthly conversion amount under the Agreement from CDN$120,000 to CDN$190,000.

In addition, the Company will issue 2,552,756 warrants to Lind in respect of the Additional Funding with an exercise price of CDN$0.1909, which is 130% of the 5-day VWAP at April 10, 2019, and exercisable for 36 months. The number of warrants issued in connection with the Additional Funding is equal to 50% of the CDN$750,000 advanced by Lind divided by the VWAP of the common shares of the company on the TSX for the five trading days immediately preceding the closing date.





Bullboard Posts